Overview
- Editors:
-
-
Phil Skolnick
-
Laboratory of Neuroscience, National Institutes of Health, Bethesda, USA
Access this book
Other ways to access
Table of contents (13 chapters)
-
-
- Luz Romero, Josep Ma Casanovas, Ildefons Hervás, Roser Cortés, Francesc Artigas
Pages 1-33
-
- Michael Briley, Chantal Moret
Pages 35-52
-
- Gilles Fillion, Laure Seguin, Olivier Massot, Jean-Claude Rousselle, Marie-Paule Fillion, Isabelle Cloëz-Tayarani et al.
Pages 53-67
-
-
-
-
- Nuo-Yu Huang, Richard T. Layer, Phil Skolnick
Pages 125-143
-
-
-
- Ronald S. Duman, Masashi Nibuya, Vidita A. Vaidya
Pages 173-194
-
- S. Paul Rossby, Fridolin Sulser
Pages 195-212
-
- Paul Willner, Mariusz Papp
Pages 213-234
-
- Steven M. Paul, Xin Wu, Yanbin Liang, Edward I. Ginns
Pages 235-250
-
Back Matter
Pages 251-257
About this book
In this book, leading-edge investigators offer effective strategies to improve current antidepressive therapies and suggest molecular, biological, and genetic approaches that will lead to the development of novel antidepressants. The contributors' critical reviews and commentaries illuminate our understanding of the mechanism(s) responsible for antidepressant action. The book's goal is to move beyond current biogenic amine-based concepts and therapies to the development of new and improved antidepressants that are more effective and have a more rapid onset than current.
Reviews
"This is a timely, much needed addition to the library of a psychopharmacology researcher who is interested in developing new studies in the field of antidepressant functioning or who needs a thorough update on cutting edge antidepressant pharmacology and theory."-Doody's Health Sciences Book Review Journal
Editors and Affiliations
-
Laboratory of Neuroscience, National Institutes of Health, Bethesda, USA
Phil Skolnick
